Join

Compare · AFIB vs LIVN

AFIB vs LIVN

Side-by-side comparison of Acutus Medical Inc. (AFIB) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both AFIB and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
  • LIVN is the larger of the two at $3.97B, about 71.5x AFIB ($55.6M).
  • LIVN has hit the wire 5 times in the past 4 weeks while AFIB has been quiet.
  • LIVN has more recent analyst coverage (20 ratings vs 7 for AFIB).
MetricAFIBLIVN
Company
Acutus Medical Inc.
LivaNova PLC
Price
$0.09-28.15%
$74.83+3.48%
Market cap
$55.6M
$3.97B
1M return
-
+5.57%
1Y return
-
+61.48%
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Exchange
NASDAQ
NASDAQ
IPO
2020
News (4w)
0
5
Recent ratings
7
20
AFIB

Acutus Medical Inc.

Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is based in Carlsbad, California.

LIVN

LivaNova PLC

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.